As a member of Polski Związek Pracodawców Przemysłu Farmaceutycznego (PZPPF) and Medi¬cine for Europe, Gedeon Richter Polska Sp. z o.o. fully respects the requirements of the Code of Conduct which sets out…

As a member of Polski Związek Pracodawców Przemysłu Farmaceutycznego (PZPPF) and Medi­cine for Europe, Gedeon Richter Polska Sp. z o.o. fully respects the requirements of the Code of Conduct which sets out…

Budapest, Hungary – Basel, Switzerland / Cambridge, Mass., USA – 15 September 2023 – Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) andSumitomo Pharma Switzerland (‘SMPS’) today…

Rotterdam, the Netherlands and Budapest, Hungary – 20 July 2023 – Gedeon Richter Plc. (“Richter”) and IQ Medical Ventures B.V. (“IQ Medical”) announced today that they signed a Share Purchase Agreement…

As a member of Polski Związek Pracodawców Przemysłu Farmaceutycznego (PZPPF) and Medi­cine for Europe, Gedeon Richter Polska Sp. z o.o. fully respects the requirements of the Code of Conduct which sets out…

  Approval marks fourth indication for VRAYLAR®, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement…

Budapest, Hungary – 25 October 2022 – Gedeon Richter Plc. (“Richter”) today announced that it has submitted a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and…

Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg and 3 mg versus placebo. Allergan plans to submit Supplemental New Drug Application (sNDA)…

Boulder, Colorado, USA – Budapest, Hungary – November 2017 – Gedeon Richter Plc. (“Richter”) today announced that it has entered into an exclusive license and distribution agreement with Prima-Temp Inc. (“Prima-Temp”), a US,…

Budapest, Stockholm – 12 October 2017 – Gedeon Richter Plc. (‘Richter’) and Pharmanest AB (‘Pharmanest’) today announced that Richter will commercialise Pharmanest’s SHACT (Short Acting Lidocaine) technology, a novel innovative proprietary pain relief…

Last Sunday (24th of September) Gedeon Richter participated in an activity that promotes the idea of transplantation, called “Run for New Life”. Company took part in two relays containing three…

Budapest, Hungary – 19 July 2017 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted marketing authorization to Reagila® (cariprazine) a novel antipsychotic for the treatment of schizophrenia…

Budapest, Hungary – 19 May 2017 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted…

30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million. • Finox Holding, a Swiss based biotech company engaged in the development and commercialisation of innovative…

Budapest, 10 March 2016 – Gedeon Richter Plc. will spend HUF 15 billion on an investment project to expand its biotechnology plant founded in 2012 to develop and manufacture biosimilar products, which…